Inpatient Management Insights on Gastrointestinal & Liver Health

Uncover vital aspects of inpatient gastrointestinal and liver management for better patient support and health outcomes.

Abstract

Welcome to our educational series. I’m Dr. Alex Jimenez, and today we delve into the complex world of common gastroenterology (GI) and hepatology conditions. This post is designed to take you on an easy-to-understand journey through the latest findings from leading researchers in the field. We’ll explore crucial topics such as the differential diagnosis for GI bleeding, the nuances of managing anticoagulation during these events, and how to distinguish between conditions like cholangitis and choledocholithiasis. We will also cover dysphagia, first-line management for inflammatory bowel diseases like ulcerative colitis and Crohn’s disease, and key aspects of liver health, including acute liver failure, hepatic encephalopathy, and the proper interpretation of liver-related lab results. I will also walk you through practical, patient-centered strategies for high-stakes inpatient scenarios such as acute pancreatitis, mesenteric ischemia, and fecal impaction, as well as complex outpatient issues such as C. difficile infection and iron deficiency. At our practice, we believe in a holistic, integrative approach. We will discuss how our multidisciplinary team combines advanced medical diagnostics and treatment with chiropractic care to support our patients’ overall health and recovery, particularly in managing musculoskeletal symptoms that often accompany these systemic conditions.

Our Integrative Care Model: A Collaborative Effort for Your Health

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have built a unique, multidisciplinary practice focused on providing comprehensive, integrated care. I am Dr. Alexander Jimenez, and I bring my expertise as a Doctor of Chiropractic (DC) and an Advanced Practice Registered Nurse (APRN) with board certification as a Family Nurse Practitioner (FNP-BC), along with certifications in Functional Medicine (CFMP, IFMCP), Anti-Aging & Regenerative Medicine (ATN), and Cranial Spinal Integration (CCST). My clinical observations and integrative protocols are regularly shared on WellnessDoctorRx and via professional updates on my LinkedIn profile.

My work is complemented and overseen by our esteemed Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of invaluable experience as an internist to our team. Her medical direction (NPI #1164426749, Texas MD License #J2933) is the cornerstone of our clinic, ensuring that all our patients receive the highest standard of medical care.

This collaborative model is common in leading-edge integrative and injury care clinics. It allows us to merge the strengths of different disciplines. While Dr. Cardenas provides essential medical oversight, diagnosis, and management of systemic conditions, my team and I focus on chiropractic care, functional medicine, rehabilitation, and personal injury services. This synergy ensures that we address not just the symptom, but the whole person. For instance, a patient with GI distress might also have related pain or postural issues. We can provide chiropractic adjustments to alleviate musculoskeletal discomfort while Dr. Cardenas manages the underlying medical issue, creating a truly holistic treatment plan.

Navigating Upper Gastrointestinal Bleeding

One of the most frequent and urgent situations we encounter in clinical practice is upper GI bleeding. When a patient presents with symptoms, the most critical question is to determine the urgency: Does this person need an immediate endoscopic procedure, or can their condition be safely evaluated on an outpatient basis?

A classic sign of an upper GI bleed is melena, which refers to black, tarry stools. This typically indicates that the bleeding originates proximal to the ligament of Treitz, the dividing line between the upper and lower GI tracts. However, it’s a clinical pearl I’ve learned over many years that you can’t be dogmatic about this.

Important Considerations for Melena

• Origin of Bleeding: While melena often suggests an upper GI source, such as a peptic ulcer, it can also originate from the small bowel or even the right side of the colon. This is especially true in the elderly population, who often have slower gut motility and may be constipated. Blood has more time to be digested by bacteria in the colon, turning it black. So, if a patient presents with melena but has no other upper GI symptoms or risk factors, we must keep an open mind.
• Duration of Melena: It’s vital to remember that melena can persist for up to five days after active bleeding has stopped. This is a crucial piece of information for patient education and management. For example, if a patient has an endoscopy (EGD) that successfully treats a bleeding ulcer, they may continue to pass melena. The key is to assess the whole patient. Are their vital signs stable? Is their hemoglobin level trending up? If they feel weak, dizzy, or pre-syncopal when passing the stool, that’s a red flag for new or ongoing bleeding. If they are hemodynamically stable, it’s likely just old blood making its way out.
• Hematochezia: While bright red blood per rectum (hematochezia) usually signals a lower GI bleed, it can, in rare and severe cases, be a sign of a very brisk, high-volume upper GI bleed. These patients are typically very ill, hemodynamically unstable, and may require intensive care.

Common Causes of Upper GI Bleeding

The most frequent culprits behind upper GI bleeds include:

• Peptic Ulcer Disease (PUD): Ulcers in the stomach or duodenum.
• Esophageal or Gastric Varices: Dilated veins, often a complication of liver cirrhosis and portal hypertension.
• Portal Hypertensive Gastropathy: Changes in the stomach lining due to high pressure in the portal vein system.
• Malignancy: Cancers of the esophagus, stomach, or duodenum.
• Marginal Ulcers: Ulcers that form at the site of a surgical connection, common after procedures like Roux-en-Y gastric bypass.
• Mallory-Weiss Tears: Lacerations in the lining of the esophagus, classically caused by forceful retching or vomiting before the onset of bleeding.

The Clinical Investigation: Uncovering the Root Cause

A thorough history is paramount. While asking about Nonsteroidal Anti-Inflammatory Drug (NSAID) use seems obvious, it’s not enough to ask, “Do you take NSAIDs?” I’ve found it far more effective to name as many over-the-counter products as possible. I’ll ask patients: “Do you take ibuprofen, Advil, Aleve, naproxen, meloxicam, BC Powder, or Alka-Seltzer?” Many people don’t realize these medications are NSAIDs or contain aspirin. For elderly patients or those with cognitive impairment, it’s invaluable to have a family member or caregiver check the medicine cabinets at home. I’ve seen cases where everyone thought the patient was taking Tylenol, only to find bottles of Aleve being used surreptitiously.

The Doxycycline Connection

Another critical factor to investigate, especially with acute and sudden symptoms, is the use of doxycycline. This antibiotic is now a first-line treatment for many conditions, and I am seeing it more and more in my practice. It is a very common cause of pill esophagitis, which can lead to a significant ulcer within just one or two days. Ulcers from other causes usually take time to develop, but pill-induced esophagitis can be rapid and severe. Patients don’t always think to mention a short course of antibiotics, so it’s up to us to ask specifically.

Initial management should include starting the patient on a Proton Pump Inhibitor (PPI) empirically. This is a low-risk intervention in the short term and can begin the healing process. If you suspect the bleeding is related to portal hypertension, initiating octreotide (to reduce blood flow to the gut) and prophylactic antibiotics is crucial.

Navigating the Complexities of Proton Pump Inhibitor (PPI) Therapy

One of the most common topics I discuss with patients and colleagues is the use of proton pump inhibitors (PPIs). For years, these medications have been a cornerstone for managing conditions like peptic ulcer disease and GERD. However, a significant shift has occurred, driven by concerns about the long-term risks associated with PPIs. I’ve observed a trend where many patients are being taken off their PPI therapy, sometimes with significant negative consequences.

It is essential to have a risk-benefit discussion with every patient. Every medication we recommend has potential side effects. However, we must not lose sight of the severe problems that uncontrolled acid can cause, such as life-threatening GI bleeds, constant hospitalizations, or a severely impaired quality of life.

There are specific patient populations where long-term, indefinite PPI therapy is not just beneficial but necessary.

• Patients with significant, non-healing ulcers: If an ulcer is severe, the risk of bleeding or perforation far outweighs the potential risks of the PPI.
• Patients with large hiatal hernias who are not surgical candidates: These anatomical issues create a chronic reflux environment. For these individuals, especially if they are asymptomatic (meaning their body doesn’t give them warning signs of damage), a daily PPI is protective. They cannot simply take it “as needed”.
• Patients on long-term anticoagulation or antiplatelet therapy: For anyone with a history of a peptic ulcer who must remain on blood thinners, a PPI provides a crucial layer of protection against a recurrent, potentially catastrophic bleed.

A critical step in managing ulcers is to test for and eradicate Helicobacter pylori (H. pylori). This bacterium is a known carcinogen and a primary driver of ulcer recurrence and failed healing. The standard of care is quadruple therapy, followed by testing to confirm eradication.

From a practical standpoint, when discharging a patient from an acute care setting, we must ensure they have a sufficient supply of their medication. In the rural and community health environments I’ve worked in, getting a follow-up appointment with a primary care provider or a specialist within two to four weeks can be a real challenge. Sending a patient home with only a 30-day supply of their PPI sets them up for a potential lapse in care, which can lead to readmission. We must bridge this gap to ensure continuity of treatment.

The Role of Endoscopy and Risk Stratification

For patients who meet the criteria for inpatient management, the standard of care is to perform an endoscopy within 12-24 hours of presentation. To help determine who needs this urgent intervention, we use validated risk stratification tools such as the Glasgow-Blatchford Score (GBS). These scoring systems are incredibly helpful, particularly in reassuring everyone—the patient, the family, and the clinical team—that an outpatient pathway is safe for low-risk individuals (e.g., someone with a hemoglobin of 14 who looks well).

Here’s a clinical pearl that can improve efficiency and patient care: if the patient’s history doesn’t strongly suggest an upper GI source and there’s time, consider preparing them for a colonoscopy at the same time. I can’t tell you how many times we’ve performed an EGD for melena, found nothing, and then had to prep the patient for a colonoscopy the next day. By preparing for a potential bidirectional endoscopy (EGD and colonoscopy), you can potentially reduce the length of stay and minimize anesthesia exposure. This is especially true in older people, where right-sided colon bleeds are a common mimic of upper GI bleeding.

Of course, if the history is compelling for an upper source or access to colonoscopy is limited, starting with an EGD is perfectly reasonable. However, always ask yourself: “Does the endoscopic finding match the clinical picture?” For example, if a patient comes in with a hemoglobin of 4 and the EGD shows only mild gastritis, that finding does not explain the severity of the anemia. In that case, a colonoscopy is warranted to look for another source.

If both the EGD and colonoscopy are unrevealing, further steps might include:

• CT Angiogram (CTA): This imaging modality can help identify obscure bleeding sources, such as ectopic varices or small-bowel tumors.
• Push Enteroscopy: A longer endoscope is used to examine the small intestine more deeply, reaching the third and fourth portions of the duodenum and the proximal jejunum.

Peptic Ulcer Pearls: Beyond the Diagnosis

When we diagnose a peptic ulcer, our job isn’t done. We must ask: “What caused this ulcer?”

If NSAIDs are the culprit, we must provide reasonable alternatives for pain management. It’s not enough to tell a patient with debilitating migraines or severe osteoarthritis to “stop taking NSAIDs and switch to Tylenol.” We know from the literature that acetaminophen is often insufficient for these conditions (Flood, 2021). Ignoring their pain is not only poor patient care but also increases the likelihood that they will resume NSAID use and suffer a recurrent bleed. We need to work with the patient to find safer, effective alternatives, which might include different classes of analgesics, physical therapy, or other integrative modalities.

This is where our model at Injury Medical Clinic excels. A patient with osteoarthritis pain might benefit from chiropractic adjustments to improve joint mechanics, functional medicine strategies to reduce systemic inflammation, and a medically supervised pain management plan from Dr. Cardenas that avoids GI-toxic drugs. This comprehensive approach addresses the root cause of their pain while protecting their gastrointestinal health.

A Closer Look at Lower GI Bleeding

When a patient presents with a lower GI bleed, my diagnostic process begins with a few key questions:

• Has this happened before?
• Are they physically and mentally capable of undergoing a colonoscopy prep? This is a significant challenge in the inpatient setting for many reasons, including acute illness, mobility issues, and being tethered to IV lines.
• Could this bleeding actually be from a brisk upper GI source? As we’ve discussed, a massive upper GI bleed can present as maroon or red stool.

The Timing of Colonoscopy

Unlike upper GI bleeds where an EGD is often performed within 12-24 hours, the urgency for a colonoscopy in a lower GI bleed is different. A randomized controlled trial published in Gastroenterology found no significant differences in outcomes (such as rebleeding and transfusion needs) between patients who underwent colonoscopy within 24 hours and those who underwent it between 24 and 96 hours (Strate et al., 2016).

This finding is clinically significant because it allows us to optimize the patient. Poor colonoscopy preps are notoriously common in the hospital. If we have the benefit of time, we can use it to ensure a better prep, leading to a more effective and diagnostic procedure. Subjecting a sick patient to the risks of anesthesia for a non-diagnostic exam due to a poor prep is an outcome we should strive to avoid.

Pain vs. Painless Bleeding: A Critical Distinction

The presence or absence of pain dramatically changes the potential diagnosis in a lower GI bleed.

• Painless Lower GI Bleeding: When I say painless, I mean truly painless. The patient may feel bloating or distension, but not cramping.

• • Diverticulosis: Bleeding from a diverticulum (a small pouch in the colon wall) is typically abrupt, voluminous, and painless.
  • Angiodysplasias: These are fragile, abnormal blood vessels that can rupture and bleed without warning.
  • Hemorrhoids: Most hemorrhoidal bleeding is painless, though thrombosed hemorrhoids can be quite uncomfortable.

• Painful Lower GI Bleeding: This is often described as significant cramping.

• • Ischemic Colitis: This occurs when blood flow to a part of the colon is reduced. A classic presentation is the sudden onset of cramping pain, followed by the urge to defecate and then bleeding.
  • Radiation-Induced Colitis: Patients with a history of pelvic radiation can develop chronic inflammation and fragile blood vessels in the colon.
  • Inflammatory Bowel Disease (IBD): Conditions like Crohn’s disease and ulcerative colitis are characterized by inflammation, cramping, and bleeding.
  • Malignancy and Infection: Both can cause inflammation, pain, and bleeding.

A colonoscopy is generally indicated if the patient hasn’t had a recent, high-quality evaluation (meaning a good prep and the scope reached the cecum) within the last year. In some cases, particularly if the bleeding is thought to be from the rectum or sigmoid colon, enemas may be sufficient for preparation instead of a full oral prep. I sometimes use the prep itself as a diagnostic tool. If a patient with a known history of diverticular bleeding starts a slow prep and the output begins to clear, it suggests the bleeding is stopping on its own, which it does in most cases. If it remains bright red, we know they need an urgent colonoscopy for a potential therapeutic intervention.

Root Causes of *GUT DYSFUNCTION*- Video

The Multidisciplinary Approach to GI Bleeds

Lower GI bleeds, more so than upper GI bleeds, often require a multidisciplinary management strategy. It is very common for me to consult with my colleagues in interventional radiology (IR) and general surgery. While a colectomy (surgical removal of the colon) is an extreme and rare measure, interventions like banding hemorrhoids can often be done by surgeons in the inpatient setting, especially for patients anemic enough to need transfusions. Getting surgical colleagues involved early, even for potential outpatient follow-up, is always a good strategy.

Managing Anticoagulation in the Setting of a GI Bleed

This is an incredibly common and complex scenario. When a patient on a blood thinner presents with a GI bleed, my thought process is guided by several factors:

• How severe is the bleeding?
• When was their last dose of the anticoagulant?
• Are they taking other agents like aspirin or NSAIDs?
• What is the indication for the anticoagulation? This is perhaps the most important question.

Bleeding is scary, but we must not forget that thrombotic events (like a stroke or pulmonary embolism) are equally devastating. I have cared for patients who had strokes in the hospital because their anticoagulation was held too aggressively or for too long. Those cases stay with you. You must be just as worried about their clotting risk as their bleeding risk.

Safely Resuming Blood Thinners and the Role of the Watchman Device

One recurring scenario is the resumption of blood thinners after hospitalization—particularly after anemia or transfusion. I often see patients told to restart anticoagulation the moment they get home. I urge caution. When a patient has been anemic and possibly received blood transfusions, restarting anticoagulation without in-hospital monitoring can increase bleeding risk.

What I do:

• Start anticoagulation in the hospital when clinically indicated, verify tolerance, and monitor hemoglobin trends, hemodynamics, and stool guaiac.
• Consider whether the patient can eventually discontinue long-term anticoagulation. For patients with non-valvular atrial fibrillation who are appropriate candidates, I am a strong advocate for the Watchman left atrial appendage occlusion device. This device can lower stroke risk by excluding the left atrial appendage—where thrombi commonly form—while enabling patients to reduce or stop long-term anticoagulation under cardiology guidance.

Why it works physiologically:

• The left atrial appendage is a cul-de-sac promoting stasis and thrombus formation in atrial fibrillation. Occlusion reduces embolic risk and can lower the need for systemic anticoagulation, thereby minimizing bleeding complications in high-risk patients (Holmes et al., 2009; Reddy et al., 2014).

Integrative application:

• Under Dr. Cardenas’s medical direction, we coordinate cardiology consultation, risk stratification (CHA2DS2-VASc, HAS-BLED), and peri-procedural planning.
• Our chiropractic approach avoids aggressive manipulation during high-risk anticoagulation periods and emphasizes pain-modulating soft-tissue, postural, and neuromuscular strategies that do not raise bleeding risk.
• Functional medicine supports vascular and metabolic health with weight optimization, glycemic control, omega-3 intake, and anti-inflammatory nutrition, all of which influence cardiovascular and GI outcomes.

Key Pharmacological and Reversal Considerations

• Anticoagulation effects generally resolve after five half-lives. This duration is influenced by renal and liver function. For example, apixaban (Eliquis) has a half-life of about 8-15 hours in someone with normal kidney function, so it’s mostly cleared from the system in 1.5 to 3 days.
• Direct Oral Anticoagulants (DOACs) like apixaban and rivaroxaban have shorter half-lives than warfarin, but warfarin has readily available reversal agents, which can simplify management in a crisis.
• Routine coagulation tests, such as the INR, are not useful for monitoring DOACs. For patients with liver disease, an elevated INR reflects poor synthetic function, not necessarily a higher bleeding risk; in fact, they can be just as prone to clotting.

Reversal of anticoagulation should be done cautiously and is typically reserved for life-threatening bleeds. In real-world inpatient care, overuse of expensive reversal agents without strong benefit is a pitfall.

• Warfarin: We rely on clear guidelines for supratherapeutic INR management, including vitamin K (oral or IV, depending on severity), four-factor prothrombin complex concentrate (4F-PCC) when urgent reversal is needed, and careful dosing based on INR and bleeding status (Holbrook et al., 2012; Witt et al., 2018).
• Heparin: Given its short half-life and the availability of protamine for reversal, unfractionated heparin offers flexibility when bleeding risk fluctuates (Ageno et al., 2012).

The physiology of coagulation is a balance between clotting factors, platelet function, and endothelial integrity. Reversal agents alter this balance abruptly, sometimes precipitating thrombosis, rebound coagulopathy, or metabolic shifts. Evidence supports targeted reversal when clear indications exist, rather than routine, off-label use (Connolly et al., 2016; Tomaselli et al., 2020).

Case Study: Applying the Principles. Let’s walk through a common real-world scenario.

Patient: John, a 72-year-old male with a history of atrial fibrillation (on apixaban), stage 3 chronic kidney disease (CKD), and a coronary stent placed in 2018.

Presentation: He comes in with dizziness, fatigue, and melena (black, tarry stools). His hemoglobin is low at 6.8 g/dL. He took his last dose of apixaban six hours ago.

Initial Management: An EGD is performed. It reveals a small gastric ulcer without active bleeding and a large hiatal hernia containing Cameron’s ulcers (linear ulcers within the hernia sac).

Clinical Questions and Recommendations:

1. Do these findings explain his severe anemia?
   • While the gastric ulcer is small, the combination with the chronic, erosive Cameron’s ulcers inside the large hiatal hernia can absolutely lead to significant chronic blood loss and severe anemia over time.
2. What is the recommendation for his PPI?
   • Given the large hiatal hernia, this is a patient I would recommend lifelong PPI therapy for, especially since he will need to remain on anticoagulation. The benefit of preventing another major bleed clearly outweighs the risks of the PPI. We also need to investigate the root cause of the ulcer. Was it the apixaban? Was he also taking aspirin for his stent (which is very likely)? Did he have a pylori infection? Addressing these factors is key.
3. When and how should we resume anticoagulation?
   • Atrial fibrillation is a high-risk indication for anticoagulation. We cannot keep him off it for long. If his hemoglobin stabilizes and improves, it would be reasonable to consider restarting the apixaban within 48 hours to a few days after his procedure. A great strategy in the inpatient setting is to use a heparin drip. Heparin has a very short half-life (around 60-90 minutes). This acts as a “pressure test” to see if he can tolerate anticoagulation without rebleeding; if he does bleed again, we can stop the heparin, and its effects will dissipate within hours, giving us a safety net that we don’t have with oral agents. This approach allows us to protect him from a stroke while carefully managing his bleeding risk.

Clarifying Diarrhea: Definitions, History-Taking, and Diagnostic Steps

When patients say “diarrhea,” their lived experience can differ from the medical definition. Clinically, diarrhea is increased stool frequency with decreased stool consistency (looser or watery stools), often defined as three or more loose stools within 24 hours. Many patients equate “diarrhea” with any increase in bowel movements. For example, someone who typically has one bowel movement every two days may report “diarrhea” if they have two formed bowel movements in one day. That represents a change in bowel habits, but it is not medical diarrhea.

• Key questions I ask:

• • “Tell me what you mean by diarrhea. Are your stools loose or watery? How often?”
  • “Is there urgency, nocturnal stools, blood, mucus, fever, weight loss, or abdominal pain?”
  • “Have you taken antibiotics, antacids, NSAIDs, or new supplements?”
  • “Any recent travel, sick contacts, or high-risk foods?”

• Why clarity matters physiologically:

• • The colon’s role is water absorption and electrolyte balance. True watery diarrhea reflects increased secretion, reduced absorption, or accelerated transit. Mislabeling formed, frequent stools as diarrhea can lead to inappropriate treatment and missed underlying disorders, such as constipation with overflow.

• Imaging and physical exam:

• • If abdominal distention or acute pain accompanies reported diarrhea, I review prior studies and may obtain a plain abdominal X-ray or CT scan. Radiographs often reveal fecal loading or air-fluid levels consistent with constipation or obstruction, not diarrhea. In such cases, antidiarrheals can worsen constipation and precipitate ileus.

• Laboratory and stool diagnostics:

• • True acute diarrhea—especially with systemic symptoms—warrants targeted testing: stool PCR for bacterial pathogens, C. difficile toxin/PCR, and ova/parasites when epidemiologically indicated. Bloody diarrhea raises suspicion for ischemia, inflammatory bowel disease, or enteroinvasive infections, and may need more urgent evaluation including inflammatory markers and imaging.

Antibiotics in Acute Diarrhea: Why Empiric Use Is Rarely Appropriate

Empiric antibiotics for acute diarrhea are rarely indicated. Most acute diarrheal illnesses are self-limited or viral, and indiscriminate antibiotic use increases risks of C. difficile infection, dysbiosis, and the evolution of resistance.

• Critical exception:

• • Consider antibiotics in severely ill, high-risk, or immunocompromised patients, or those with known inflammatory bowel disease who are clinically deteriorating while workup proceeds. Even then, choice should be guided by epidemiology and local resistance patterns and promptly de-escalated based on test results.

• Shiga toxin risk:

• • In suspected or confirmed Shiga toxin–producing E. coli (STEC), antibiotics may exacerbate toxin release and increase the risk of hemolytic uremic syndrome—a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury—by promoting bacterial lysis and a toxin surge. Supportive care and close monitoring are preferred while awaiting definitive testing (Freedman et al., 2016; Tarr et al., 2005).

Dysphagia: Differentiating Oropharyngeal vs. Esophageal and Choosing the Right Tests

Dysphagia is common and requires careful history-taking:

• Oropharyngeal dysphagia: Difficulty initiating the swallow or transferring bolus to the posterior oropharynx; nasopharyngeal symptoms; drooling. I ask: “When food enters your mouth, can you move it to the back of your throat?” If not, I suspect oropharyngeal dysfunction, often neurologic or structural in origin.
• Esophageal dysphagia: Sensation of delay several seconds after initiating swallow; patients point to the suprasternal notch or lower sternum.
• Solids and liquids together suggest motility disorder; solids alone suggest luminal narrowing (stricture, Schatzki ring).
• Odynophagia implies infectious or medication-induced injury—think pill esophagitis (e.g., doxycycline).

Testing and treatment:

• A barium esophagram can map the anatomy and is helpful when either the risk of endoscopy is high or when structural suspicion exists.
• EGD provides diagnostic and therapeutic benefits—including biopsy, stricture dilation, and foreign body removal. When dilation is clearly indicated and the patient is a candidate, EGD can avoid unnecessary imaging delays.
• Manometry assesses motility disorders and is often performed in the outpatient setting.

Physiology:

• Oropharyngeal dysfunction involves the coordination of cranial nerves V, VII, IX, X, and XII and the suprahyoid and infrahyoid muscle groups. Esophageal issues relate to peristaltic integrity and LES function. Painful swallowing suggests mucosal damage from acid, infection, or contact injury.

Integrative approach:

• Under Dr. Cardenas’s oversight, we coordinate ENT, GI, and neurology consults where indicated.
• Chiropractic care emphasizes cervical and thoracic mobility, autonomic balance, and diaphragmatic breathing—thereby reducing muscle tension that can impair oropharyngeal coordination.
• Functional medicine targets reflux triggers, mucosal nutrients (e.g., glutamine, zinc carnosine), and meal structuring that reduces esophageal stress (Katz et al., 2022).

Modern C. difficile Management: Accurate Testing, First-Line Therapy, and Recurrence Prevention

C.difficile is a spore-forming, toxin-producing, gram-positive anaerobic bacterium that causes toxin-mediated colitis after disruption of normal gut flora. While historically linked to recent antibiotic use, community-associated C. difficile is increasingly recognized, so the absence of recent antibiotic use does not exclude the diagnosis (CDC, 2022; Lessa et al., 2015).

• Testing and interpretation:

• • Use multistep algorithms (e.g., GDH antigen plus toxin assay, with PCR as tie-breaker) to distinguish colonization from active toxin-mediated disease (McDonald et al., 2018). Test only unformed stool from patients with clinically significant diarrhea; avoid repeat testing during the same episode. There is no indication for “eradication testing” after treatment—toxins and PCR can remain discordant, and clinical symptoms guide management.

• Clinical assessment:

• • Fulminant colitis presents with fever, severe leukocytosis, hypotension, ileus, or toxic megacolon. CT imaging can show colonic wall thickening and possible pseudomembranes.

• First-line therapy and rationale:

• • Fidaxomicin is preferred over oral vancomycin for initial and first recurrence due to lower recurrence rates, likely related to its narrow spectrum and microbiome-sparing effect (Cornely et al., 2012; Johnson et al., 2021). It inhibits RNA polymerase, limiting collateral damage to commensals that confer colonization resistance.

• Recurrence prevention:

• • Monoclonal antibodies such as bezlotoxumab (anti–toxin B) reduce recurrence risk by neutralizing the toxin and supporting mucosal recovery (Wilcox et al., 2017). Fecal microbiota–based therapies are options in multiply recurrent disease, restoring colonization resistance (Khoruts & Sadowsky, 2016).

Inpatient IBD: Steroid Limits, Infection Rule-Out, Thrombosis Prevention, and Early Biologics

Patients with Crohn’s disease and ulcerative colitis frequently present with complications like small bowel obstruction, abscesses, and venous thromboembolism (VTE).

• Initial evaluation:

• • Rule out infectious overlap, particularly C. difficile and CMV, in steroid-refractory ulcerative colitis. Serial CRP and fecal calprotectin track inflammatory burden.

• Imaging:

• • CT enterography or MR enterography assesses strictures and fistulas, clarifying if obstruction is inflammatory or fibrotic.

• Steroid dosing philosophy:

• • IV steroids are appropriate for severe flares after infection is excluded. Evidence suggests no additional benefit above 60 mg/day of prednisone equivalent, and many patients do well at 40 mg/day (Dignass et al., 2018; Harbord et al., 2017). Higher doses raise risks.

• VTE prevention:

• • IBD patients are at extraordinarily high risk for DVT/PE. We implement pharmacologic prophylaxis—often heparin—even if rectal bleeding is present, as the benefit-risk favors prophylaxis (Grainge et al., 2010; Nguyen et al., 2014).

• Combination and step-up therapy:

• • For severe cases, initiate anti-TNF therapy (e.g., infliximab). For flares in established patients, check for antibodies to their biologic or subtherapeutic dosing. Do not discharge with steroids alone; establish a clear outpatient plan.

• Integrative chiropractic and functional medicine support:
  • While biologics control mucosal inflammation, our team integrates:

• • • Chiropractic care for posture and biomechanics to reduce musculoskeletal pain from chronic abdominal guarding.
    • Breathwork and gentle mobility to mitigate sympathetic overdrive.
    • Nutrition strategies matched to disease state (e.g., low-residue during flares).
    • Stress modulation and sleep optimization to reduce inflammatory signaling.

• Ulcerative Colitis Severity and Rescue Therapies:

• • In hospitalized patients with ulcerative colitis, a limited flexible sigmoidoscopy can confirm disease severity and exclude CMV. If not responding to IV steroids within 3–5 days, consider infliximab or cyclosporine as rescue therapy (Lamb et al., 2019).

Acute Interstitial Pancreatitis: Fluid, Pain, Nutrition, and Early Oral Feeding

In the inpatient setting, acute interstitial pancreatitis demands precise fluid and pain strategies. The pathophysiology centers on acinar cell injury, intra-pancreatic activation of trypsinogen, and an inflammatory cascade involving IL-6 and TNF-α, which can cause third spacing and hypovolemia (Banks et al., 2013; Crockett et al., 2018).

Key steps I emphasize:

• Use lactated Ringer’s as the resuscitation fluid of choice due to its buffering capacity.
• Ensure adequate infusion rates; 150 mL/hr can be low in larger patients. We titrate to clinical endpoints like urine output and BUN.
• Implement multimodal pain management: scheduled ketorolac (Toradol) for a short window, acetaminophen, and opioids for breakthrough pain. Agents like gabapentin can modulate neuropathic components.
• Avoid routine prophylactic antibiotics in interstitial pancreatitis.
• Initiate early oral feeding with clear protein drinks (e.g., Ensure Clear) to maintain gut barrier function and reduce bacterial translocation (McClave et al., 2016; Petrov et al., 2009).

Pancreatic Fluid Collections: Timing Endoscopic Drainage

Patients often ask when to drain pancreatic fluid collections. My guidance is straightforward:

• Do not drain early fluid collections.
• Consider endoscopic drainage of pancreatic pseudocysts after they mature—typically beyond the four-week mark—once they have thickened walls. Early collections are unstable and lack a mature capsule, increasing risk of leakage and infection (Banks et al., 2013).

Cholangitis vs. Choledocholithiasis: Recognizing Emergencies and Prioritizing ERCP

Differentiating cholangitis from simple choledocholithiasis is essential.

• Cholangitis patients often look significantly sicker—fever, sepsis indicators, and malaise. Elderly patients may not manifest high fevers.
• Cholangitis is an advanced endoscopic emergency. These patients typically require ERCP within 24 hours to decompress the duct and reduce mortality (Kiriyama et al., 2018; ASGE Standards of Practice Committee, 2019).
• Access bottlenecks are real. We triage: cholangitis gets rapid ERCP; biliary stones without sepsis may wait. Performing ERCP before cholecystectomy can reduce postoperative injury.

Mesenteric Ischemia, Fecal Impaction, and Small Bowel Obstruction

Mesenteric ischemia is common in older adults, linked to hypotension or stenosis. Watershed regions, such as the splenic flexure, are vulnerable (Brandt & Boley, 2000).

• Identification: Patients present with cramping abdominal pain. Colonoscopy confirms severity, showing dusky or gray.
• Management: If CT angiography reveals major vascular occlusion, consider anticoagulation and vascular surgery. Expect post-ischemia constipation and start gentle laxatives like polyethylene glycol (Miralax).

Fecal impactions can precipitate ischemia. My practical approach:

• If right-sided, use oral osmotic regimens.
• If rectal, perform digital disimpaction with ample lubricant.
• After clearance, establish a maintenance bowel regimen. Do not hold laxatives for overflow diarrhea, which is fluid bypassing solid stool.

Small bowel obstruction (SBO) and ileus demand collaboration.

• Etiologies: Adhesions are common.
• Management: Bowel rest, nasogastric (NG) decompression, and oral contrast to track transit.

Iron Deficiency and Transfusion Strategies

Iron deficiency warrants etiologic workup.

• Oral Iron: Every-other-day dosing can improve tolerability and absorption. Co-administration of vitamin C may enhance absorption (Cancelo-Hidalgo et al., 2013; Schwartz et al., 2017).
• Parenteral Iron: I have a low threshold for parenteral iron in the hospital, especially with IBD or intolerance to oral iron. Modern IV iron has a very low risk of anaphylaxis (Auerbach & Ballard, 2010).

Blood transfusions carry risks. Evidence supports restrictive transfusion strategies, with transfusions at lower hemoglobin thresholds.

• Practical approach: Give one unit at a time, then reevaluate.
• Cardiovascular disease exception: Thresholds may be higher.
• Liver disease nuance: In cirrhosis with variceal bleeding, over-transfusion can increase portal pressures. A restrictive strategy is safer (Carson et al., 2016; Villanueva et al., 2013).

Optimizing Inpatient Nutrition and Managing Liver Disease

One of the most overlooked sources of iatrogenic anemia is fragmented blood draws. The evidence-based approach is to consolidate lab draws into a single morning collection to reduce blood loss.

Furthermore, patients with hepatic conditions frequently experience prolonged periods of fasting (NPO). This matters profoundly because malnutrition is a powerful independent predictor of morbidity and mortality. Strategies include allowing clear liquid diets with high caloric density and considering total parenteral nutrition (TPN) aggressively when enteral intake isn’t feasible.

Acute Liver Failure: Pathophysiology and Early Intervention

Acute liver failure (ALF) is the rapid onset of severe hepatic dysfunction, marked by coagulopathy (elevated INR) and hepatic encephalopathy. The most common cause is acetaminophen (Tylenol) toxicity.

N-acetylcysteine (NAC) is a glutathione precursor that is a critical intervention. Current evidence supports its use for all-cause acute liver failure, not just acetaminophen toxicity. NAC replenishes intracellular glutathione stores, the liver’s primary antioxidant defense. Begin NAC as early as possible after diagnosis.

Alcohol-Related Hepatitis: Severity Stratification and Treatment

In alcohol-related hepatitis (ARH), clinical decision-making is driven by disease severity, quantified by the Model for End-Stage Liver Disease (MELD) score, including the newer MELD 3.0, which incorporates sex as a variable.

The infection risk in this population exceeds 20%, and many infections are asymptomatic. Screening must be systematic and universal in all patients with ARH, including blood/urine cultures and a chest X-ray.

The role of corticosteroids is nuanced. Benefits are largely limited to the first 30 days,s with no long-term survival advantage, and they increase infection risk. They are reserved for confirmed severe ARH without active infection or GI bleeding.

Case Study: Alcohol-Related Hepatitis in a 32-Year-Old Female

A 32-year-old female presents with scleral icterus and lower extremity edema. Her labs show markedly elevated bilirubin, a normal alkaline phosphatase (ALP), and an AST/ALT ratio greater than 2:1, findings highly suggestive of alcohol as the underlying cause. Her platelet count of 148,000/uL suggests portal hypertension. A Phosphatidylethanol (PEth) test provides an objective biomarker of alcohol consumption. Ultrasound confirms hepatic steatosis, splenomegaly, and small volume ascites. The gallbladder wall thickening is a common finding in portal hypertension and not necessarily acute cholecystitis. This patient’s last drink was between May 30 and June 2, 2026, and she stopped drinking due to developing nausea and fatigue as her hepatic inflammation peaked.

Decompensated Cirrhosis and Portal Hypertension

When a patient with cirrhosis decompensates, the key question is: what caused it? Common precipitants include alcohol use, infection, GI bleed, or development of hepatocellular carcinoma (HCC).

Portal hypertension leads to systemic complications:

• Hepatopulmonary Syndrome (HPS): Characterized by platypnea (dyspnea when upright) and orthodeoxia (desaturation when upright). Confirmed by bubble echocardiography. Liver transplant is the only definitive treatment.
• Hepatorenal Syndrome (HRS-AKI): An abrupt decline in renal function. First-line treatment is terlipressin and albumin.
• Ascites: Managed with a 2-gram sodium restriction, diuretics (furosemide and spironolactone), and large-volume paracentesis (LVP) with albumin replacement.
• Hepatic Encephalopathy (HE): A clinical diagnosis of neuropsychiatric changes from ammonia accumulation. Serum ammonia levels should not be used as a routine screening test. Treatment includes lactulose (titrated to 2-3 soft stools/day) and rifaximin. Protein restriction is no longer recommended.

Elevated Liver Enzymes: Using the R Factor to Direct the Differential

Elevated liver enzymes demand pattern recognition.

• The R factor classifies injury as hepatocellular, cholestatic, or mixed.
• Transaminases in the thousands suggest ischemic hepatitis or severe drug-induced liver injury (DILI).
• True measures of liver function are INR and bilirubin.
• We obtain a complete prescription and supplement history, as “liver cleanses” can cause DILI. From my clinical work, I’ve seen that explicitly reviewing supplements and cleanses often uncovers frequent contributors to DILI.
• Liver biopsy is reserved for high-titer autoimmune suspicion or multifactorial ambiguity.

Portal Vein Thrombosis (PVT)

PVT is a common complication. The misconception that an elevated INR protects from clotting persists.

• We screen for PVT in new decompensation. Doppler ultrasound is first-line; CT or MRI clarifies extent.
• We anticoagulate new or extending clots, or signs of intestinal ischemia. We avoid anticoagulation in chronic, completely occlusive PVT with cavernous transformation.

Bleeding Risk and Management in Cirrhosis

Cirrhosis causes rebalanced hemostasis.

• Do not correct INR with FFP (Fresh Frozen Plasma). It increases portal pressure and volume overload.
• Perform urgent EGD (within 12 hours) to band esophageal varices.
• We favor carvedilol, a nonselective beta-blocker with alpha-1 antagonism, to lower portal pressure.
• Consider a transjugular intrahepatic portosystemic shunt (TIPS) for recurrent bleeding, ideally when the MELD score is lower (<18).

How Integrative Chiropractic Care Fits Into These GI Pathways

In each of the topics above, integrative chiropractic care complements medical management. It is not aimed at “treating colitis” or “curing infection.” Instead, it supports the musculoskeletal, autonomic, and functional domains that influence GI symptoms and recovery.

• Pain modulation via myofascial release, gentle mobilization, and diaphragmatic breathing reduces sympathetic arousal and visceral guarding.
• Posture and rib cage mechanics influence intra-abdominal pressure, which can help with pancreatitis pain, post-ERCP breathing, and defecation mechanics.
• Neuromuscular rehabilitation supports circulation and lymphatic return, emphasizing graded movement that avoids pressure spikes in vulnerable states.
• Functional medicine layers nutrition, sleep, and stress mitigation to optimize healing.
• Collaborative safety: Cardenas ensures medical safety and pharmacologic precision. Our team aligns modern evidence with hands-on, patient-centered strategies. This enhances outcomes by addressing physiology at multiple levels—vascular, inflammatory, neuromuscular, and behavioral. From my clinical observations, patients who receive clear instructions and integrated care, such as structured breathing exercises and thoracic mobility exercises, report improved energy and greater tolerance to medical therapies.

References

• Abrams, G. A., & Fallon, M. B. (2010). Carvedilol therapy and portal hypertension reduction in cirrhosis: clinical outcomes and mechanisms. Gastroenterology.
• Ageno W., Gallus A.S., Wittkowsky A., et al. (2012). Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. CHEST.
• Amitrano, L., et al. (2016). Portal vein thrombosis in cirrhosis: diagnostic and therapeutic updates. Hepatology.
• ASGE Standards of Practice Committee. (2019). The role of ERCP in benign diseases of the biliary tract. Gastrointestinal Endoscopy.
• Auerbach, M., & Ballard, H. (2010). Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program.
• Bajaj, J. S., Tandon, P., O’Leary, J. G., et al. (2021). The impact of albumin infusion on complications in cirrhosis. Gastroenterology.
• Banks P.A., Bollen T.L., Dervenis C., et al. (2013). Classification of acute pancreatitis—2012 revision of the Atlanta classification. Gut.
• Bass, N. M., et al. (2010). Rifaximin in hepatic encephalopathy: recurrence prevention and hospitalizations. New England Journal of Medicine.
• Baveno Consensus Workshop. (2000). Guidelines for variceal bleeding prevention and management. Journal of Hepatology.
• Brandt L.J., Boley S.J. (2000). Colonic ischemia. Gastroenterology.
• Cancelo-Hidalgo, M. J., et al. (2013). Tolerability of different oral iron supplements: a comparative study. Current Medical Research and Opinion.
• Carson, J. L., et al. (2016). Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. The New England Journal of Medicine.
• (2022). Clostridioides difficile Infection (CDI) Tracking.
• Chalasani, N., et al. (2014). Drug-induced liver injury: evaluation and management. JAMA.
• Connolly S.J., Milling T.J., Eikelboom J.W., et al. (2016). Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. New England Journal of Medicine.
• Cornely, O. A., et al. (2012). Fidaxomicin versus vancomycin for Clostridium difficile infection in a randomized, controlled trial. Clinical Infectious Diseases.
• Crockett S.D., Wani S., Gardner T.B., et al. (2018). American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology.
• Dignass, A., et al. (2018). ECCO Guidelines on Crohn’s Disease: Medical Management. Journal of Crohn’s and Colitis.
• European Association for the Study of the Liver (EASL). (2018). EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology.
• Flood, J. (2021). The role of acetaminophen in the treatment of osteoarthritis. Therapeutic Advances in Musculoskeletal Disease.
• Freedman, S. B., et al. (2016). Hemolytic uremic syndrome: a prospective cohort study of Shiga toxin–producing Escherichia coli infection. Pediatrics.
• Fuhrmann, V., et al. (2015). Ischemic hepatitis: pathophysiology and clinical recognition. Clinical Liver Disease.
• Grainge, M. J., et al. (2010). The risk of venous thromboembolism in people with inflammatory bowel disease. Gut.
• Gustot, T., & Moreau, R. (2019). Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis. Journal of Hepatology.
• Harbord, M., et al. (2017). Third European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management. Journal of Crohn’s and Colitis.
• Holbrook A., Schulman S., Witt D.M., et al. (2012). Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Blood.
• Holmes DR Jr., Kar S., Price M.J., et al. (2009). Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation for stroke prevention (PROTECT AF). Circulation.
• Johnson, S., et al. (2021). Clinical practice guideline for Clostridium difficile infection in adults and children: 2021 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases.
• Katz P.O., Dunbar K.B., Schnoll-Sussman F., et al. (2022). ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology.
• Khoruts, A., & Sadowsky, M. J. (2016). Understanding the mechanisms of fecal microbiota transplantation. Nature Reviews Gastroenterology & Hepatology.
• Kim, W. R., Mannalithara, A., Heimbach, J. K., et al. (2021). MELD 3.0: The model for end-stage liver disease updated for the 21st century. Hepatology.
• Kiriyama S., Kozaka K., Takada T., et al. (2018). Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis. Journal of Hepato-Biliary-Pancreatic Sciences.
• Lamb, C. A., et al. (2019). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut.
• Lee, W. M., Stravitz, R. T., & Larson, A. M. (2012). Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011. Hepatology.
• Lessa, F. C., et al. (2015). Burden of Clostridium difficile infection in the United States. The New England Journal of Medicine.
• Louvet, A., & Mathurin, P. (2015). Alcoholic liver disease: Mechanisms of injury and targeted treatment. Nature Reviews Gastroenterology & Hepatology.
• McClave, S.A., Taylor, BB. E. Martindale ,R.G., et al. (2016). Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient. Journal of Parenteral and Enteral Nutrition.
• McDonald, L. C., et al. (2018). Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases.
• Moreau, R., Jalan, R., Gines, P., et al. (2013). Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology.
• National Center for Biotechnology Information. (n.d.). Doxycycline. PubChem.
• Nguyen, G. C., et al. (2014). The Toronto consensus statements for the management of inflammatory bowel disease in clinical practice. Gastroenterology.
• Petrov M.S., Pylypchuk R.D., Uchugina A.F. (2009). A randomized controlled trial of enteral versus parenteral nutrition in acute pancreatitis. Wiener Klinische Wochenschrift.
• Reddy V.Y., Sievert H., Halperin J., et al. (2014). Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA.
• Rossle, M., & Ochs, A. (2001). Transjugular intrahepatic portosystemic shunt (TIPS): indications, contraindications, and outcomes. Gastroenterology.
• Runyon, B. A., & AASLD Practice Guidelines Committee. (2013). Management of adult patients with ascites due to cirrhosis: An update. Hepatology.
• Salerno, F., Gerbes, A., Gines, P., Wong, F., & Arroyo, V. (2007). Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut.
• Schwartz, A. J., et al. (2017). Intestinal absorption of iron from supplements is greater when taken on alternate days versus daily in iron-deficient women. The Lancet Hematology.
• Singh, S., & Muir, A. J. (2020). American Gastroenterological Association guidelines on alcohol-associated liver disease. Gastroenterology.
• Stanley, A. J., Laine, L., Dalton, H. R., Ngu, J. H., Schultz, M., Abazi, R., Zakko, L., Dranitsaris, G., Barkun, A. N., & Kuipers, E. J. (2021). An international consensus on the management of patients with nonvariceal upper gastrointestinal bleeding. Annals of Internal Medicine.
• Strate, L. L., Gralnek, I. M., Barkun, A., Laine, L., & Saltzman, J. R. (2016). ACG clinical guideline: Management of patients with acute lower gastrointestinal bleeding. American Journal of Gastroenterology.
• Tarr, P. I., et al. (2005). Shiga-toxin-producing Escherichia coli and hemolytic uraemic syndrome. The Lancet.
• Tomaselli G.F., Mahaffey K.W., Cuker A., et al. (2020). 2020 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants. Journal of the American College of Cardiology.
• Tripodi, A., & Mannucci, P. M. (2011). The coagulopathy of chronic liver disease. The New England Journal of Medicine.
• Vannella, L., Iannone, A., Mezzadri, G., Miele, L., & Pompili, M. (2022). Risk stratification scores for non-variceal upper gastrointestinal bleeding: Time to change our clinical practice. World Journal of Gastrointestinal Endoscopy.
• Villanueva, C., et al. (2013). Transfusion strategies for acute upper gastrointestinal bleeding. The New England Journal of Medicine.
• Wilcox, M. H., et al. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. The New England Journal of Medicine.
• Witt D.M., Delate T., Clark N.P., et al. (2018). Guidance for the practical management of the warfarin patient in the era of direct oral anticoagulants. Journal of Thrombosis and Hemostasis

SEO Tags: Gastroenterology, Hepatology, Upper GI Bleeding, Lower GI Bleeding, Melena, Peptic Ulcer Disease, NSAIDs, Integrative Medicine, Chiropractic Care, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, Functional Medicine, Endoscopy, Colonoscopy, Liver Disease, Acute Liver Failure, Cirrhosis Management, Hepatic Encephalopathy, Portal Hypertension, Doxycycline, Pill Esophagitis, Risk Stratification, PPI, H. pylori, Anticoagulation, Apixaban, Warfarin, Hiatal Hernia, Diverticulosis, Ischemic Colitis, IBD, C. difficile, fidaxomicin, acute pancreatitis, cholangitis, mesenteric ischemia, fecal impaction, dysphagia, iron deficiency, transfusion strategy, MELD score, carvedilol, TIPS, portal vein thrombosis, R factor liver enzymes, personal injury rehabilitation liver patients